Fuad El-Hibri was interviewed a few months ago by Ricardo Karam. This interview was aired in the 2011 season on the Ricardo Karam’sShow, which focuses on successful people from the Arab community. Ricardo Karam is a well known talk show host who has interviewed many high profile people, such as Celine Dion, Charles Aznavour, Paolo Coelho, Valentino, Kofi Annan, Andre Agassi and others.

Here is a summary of the televised interview:  (Note that the interview begins in Arabic but switches to English within the first few minutes).

Born in Germany, Fuad El-Hibri came to America to be a self-proclaimed entrepreneur. With a strong ancestry from Europe and the Middle East, he believes that,“one identifies oneself by the way one is brought up.” “One never really loses one’s ancestry,” he says, as he describes his strong relationship with both a German and Middle Eastern Heritage. Being fluent in both English and Arabic, he describes language as a matter of practice and opportunity.

Born of a German mother and Lebanese father, he was brought up within multiple cultures. Having such a broad exposure to cultures, he was able to pick and choose aspects that fit his personality and life the best, creating a well-rounded lifestyle and culture that he looks fondly at.

He is a dedicated citizen to the U.S., being that the U.S. is where he lives and works. However, no matter how long he lives in the U.S. and adopts American culture, he will never forget his heritage and the cultures he originates from.

Ever since he was a young teen, El-Hibri had the goal of becoming an entrepreneur. He worked towards this goal while attending Stanford University. He views himself, “very lucky” to have all of the opportunities that were offered to him, like the ability to attend a prestigious college and obtain a good education. El-Hibri was then introduced by his father to a group of honest, hardworking businessmen that helped tojump-start his career.

His dream of becoming an entrepreneur always stemmed from wanting to do something meaningful; something that could help people’s lives, help with communication and help the environment. He did not want to create a company whose main goal was trade or simple moneymaking; profit was not his overall objective. Most importantly he wanted to build something that he and his family could be proud of.

Being very fortunate as a child and young adult, he was given the means and opportunities to make his dreams possible. Without his parents’ support, both emotionally and financially, he may never have accomplished everything he has toady. As the current CEO of Emergent BioSolutions, he was able to make his dreams come true.

Although he was given the support he needed to make his dreams become reality, none of it could have been possible without the hard work, effort and perseverance he put into his work.  Becoming an entrepreneur didn’t come easily, and could never have been achieved without the determination El-Hibri has.

Looking fondly at his culture, family and life experiences, El Hibri has become the success he always wanted to be. Through hard work and perseverance, he can say that both he and his family are proud of everything he has accomplished.

The Vilcek Foundation was established in 2000 by Jan and Marica Vilcek, immigrants from the former Czechoslovakia.  The Foundation was established with the aim of raising public awareness around immigrants’ contributions to the sciences, arts, and culture in the United States.  The Foundation’s mission was inspired by the couple’s careers in science and art, as well as their personal experiences and appreciation for the opportunities given to them as newcomers to the United States.  The Foundation showcases immigrant artists and performers in their New York gallery, awards the annual Vilcek Prizes, and sponsors numerous events such as the Santa Fe Opera and Hawaii International Film Festival.

In the 2010 Spring newsletter, the Vilcek Foundation recognized Fuad El-Hibri, Chairman and CEO of Emergent BioSolutions, Inc.  This is a summary of their report.  The original can be found here:

http://www.vilcek.org/news_articles/newsletters/2010/spring/newsletter_spring2010.html

In addition to his accomplishments in the business world, El-Hibri founded the El-Hibri Charitable Foundation in 2001 in honor of his father, Ibrahim El-Hibri.  The Foundation annually awards the El-Hibri Peace Education Prize to peace educators.  It also funds other programs aligned with its four part mission statement promoting Peace Education, Interfaith Dialogue, Humanitarian Aid, and Social Justice.

El-Hibri credits much of his success in the business and philanthropic world to his immigrant background. He was raised in Europe, North Africa, and the Middle East but always knew he wanted to attend college in the United States.  After being accepted to Stanford that dream became a reality.  After completing his undergraduate degree at Stanford he received his Master’s degree from Yale.  This international background instilled in El-Hibri the desire to encourage dialogue between different cultures which in 2007 lead to the annual El-Hibri Prize for Peace Education.

“We are trying to get to the crucial goal of establishing a more evident culture of peace,” said Zen Hunter-Ishikawa, Vice President of Operations at El-Hibri Charitable Foundation.  The Prize for Peace Educators awards individuals who have made major contributions to the field of peace education.  Past winners of the prize include Scott Kennedy, former Mayor of Santa Cruz, California, and Abdul Aziz Said, professor at American University in Washington D.C.

“It’s taken some time to get organized,” said El-Hibri, “So it’s only been the last few years we’ve been able to focus on our programs.  We hope to grow significantly over the years.”

NHM’s on-site museum, called The Experience Museum, is expected to be located at Atlanta Centennial Olympic Park. The facility will consist of self-guided multi-dimensional immersive presentations of life, health, and the human body, designed by BRC Imagination Arts. Renowned architect Moshe Safdie is designing the facility.

“Colman McCarthy has dedicated his life to teaching young people the principles of peaceful conflict resolution,” noted Robert Buchanan, president of the El-Hibri Charitable Foundation. “His personal commitment and example, combined with his access to national media, have inspired countless individuals to incorporate the values of peace and nonviolence in their personal and professional lives. The El-Hibri Charitable Foundation is pleased to recognize Colman McCarthy for his tireless efforts on behalf of peace education.”

McCarthy was a columnist with The Washington Post from  1969 to 1997. He also wrote for The New Yorker, The Nation, and The Atlantic, among other publications, and has been a frequent guest on C-SPAN. In addition to his career in journalism, McCarthy has been teaching courses on nonviolence and peace studies for nearly thirty years at Washington, D.C. area schools, universities, and student leadership programs. In 1985, he founded and continues to lead the Center for Teaching Peace, a non-profit organization that works with schools and individuals around the world to initiate and expand academic programs in peace education.

McCarthy’s publications include “I’d Rather Teach Peace”, “All of One Peace” and “At Rest with the Animals”.He is also the editor of two anthologies of peace essays that are used as course texts in high schools and colleges:  “Solutions to Violence” and  “Strength Through Peace”.

The  2010 El-Hibri Peace Education Prize will be awarded to Colman McCarthy at a ceremony to be held at 6:30 p.m. on September 25th at the El-Hibri Charitable Foundation’s Washington, D.C. headquarters.

The El-Hibri Charitable Foundation is a  501(c)(3) non-profit private foundation. The foundation seeks to build a better world by encouraging peace education, interfaith dialogue, humanitarian aid and social justice.The El-Hibri Peace Education Prize was initiated in  2007. Past Laureates include Abdul Aziz Said, founder of the Center for Global Peace at American University; Scott Kennedy, peace activist and co-founder of the Resource Center for Nonviolence; and Mary E. King,international educator,author and policy advisor.

For further information, visit http://www.elhibriprize.org

ROCKVILLE, MD, July 20, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it is revising upwards its 2010 annual guidance to now reflect anticipated total revenues of $275 to $300 million and net income of $40 to $50 million.  Of the anticipated total revenues of $275 to $300 million, $165 to $190 million is expected to be recognized in the second half of 2010.  This revised forecast does not reflect or incorporate any revenue impact from a possible development contract for the company’s rPA vaccine candidate.

The revision to the 2010 financial forecast is supported primarily by the recent modification to the company’s current BioThrax^® procurement contract with the US Centers for Disease Control and Prevention (CDC).  This contract modification increased the number of doses of BioThrax that the company can deliver into the Strategic National Stockpile (SNS) during calendar 2010.  This increased volume of available doses of BioThrax is due to consistently high production yields throughout 2010.

“This modification by the CDC to our existing BioThrax procurement contract reinforces, yet again, the US government’s commitment to BioThrax as a critical component of the Strategic National Stockpile and to our nation’s defense against bioterrorism,” said Fuad El-Hibri, chairman and chief executive officer of Emergent.  “This is another example of how we continue to work with our US government partners in establishing BioThrax as the backbone of our readiness against the threat of anthrax and to building a stockpile as rapidly as possible.”

Daniel J. Abdun-Nabi, president and chief operating officer of Emergent, also commented, “The production yields we have been experiencing are a direct result of our commitment to driving innovation in our manufacturing process and to a multi-year initiative focused on process optimization of the existing Building 12 production facility.  We are extremely pleased with the results of our continuous process improvement program for BioThrax and expect this program to drive the maintenance of positive production metrics going forward.”

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body’s immune system to prevent or treat disease.  Emergent’s marketed product, BioThrax^® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection.  Emergent’s product pipeline targets infectious diseases and includes programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia.  Additional information may be found at www.emergentbiosolutions.com.

About BioThrax^®

BioThrax is the only FDA-licensed vaccine for the prevention of anthrax infection.  It is indicated for the active immunization of adults who are at high risk of exposure to anthrax.  BioThrax is manufactured from a culture filtrate, made from a non-virulent strain of Bacillus anthracis.  Since 1998, the U.S. government has procured over 45 million doses of BioThrax.  During that time period, more than 9.6 million doses have been administered to nearly 2.4 million military personnel.  For full prescribing information, please visit www.biothrax.com/prescribinginformation_biothrax_us.pdf.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including any potential future securities offering, our expected revenue growth and net earnings for 2010, and any other statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions, are forward-looking statements. There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements, including appropriations for BioThrax^® procurement; our ability to obtain new BioThrax^® sales contracts; our plans to pursue label expansions and improvements for BioThrax^®; our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance and clinical utility of our products; the success of our ongoing and planned development programs, preclinical studies and clinical trials; our ability to identify and acquire or in license products and product candidates that satisfy our selection criteria; the potential benefits of our existing collaboration agreements and our ability to enter into selective additional collaboration arrangements; the timing of and our ability to obtain and maintain regulatory approvals for our other product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our manufacturing success rates; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2010 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Emergent BioSolutions Inc. (NYSE:EBS) is hosting “Bioterrorism Prevention, Preparedness and Response,” a forum organized for members of the North Atlantic Treaty Organization (NATO) Parliamentary Assembly (PA) to raise global awareness of the importance of biopreparedness. The visiting delegation is composed of parliamentarians from Canada, Estonia, France, Finland, Germany, Greece, Italy, Hungary, Lithuania, the Netherlands, Norway, Romania, Poland, Portugal, Turkey, Sweden, Slovenia, Spain, and the United Kingdom.

“Emergent commends NATO parliamentarians for advancing the international dialogue on biopreparedness,” said Allen Shofe, senior vice president public affairs, Emergent BioSolutions. “We are pleased to share our knowledge based on Emergent’s extensive experience in the development, manufacture, and delivery of medical countermeasures that are critical to the U.S. government’s biodefense infrastructure.”

The forum features biodefense expert Dr. Robert Kadlec, Director of PRTM Biodefense and Public Health Practice, who will discuss the United States’ approach to bioterrorism prevention, including best practices and strategies such as funding, development, and manufacture of biodefense medical countermeasures, creation of strategic stockpiles, and cooperation within the international community.

Emergent BioSolutions’ senior management team, headed by Daniel J. Abdun-Nabi, President and Chief Operating Officer, Dr. Tevi Troy, Senior Visiting Fellow at the Hudson Institute and former Deputy Director of the U.S. Department of Health and Human Services, and Dr. Barry Kellman, President of the International Security and Biopolicy Institute (ISBI) are among the attendees. The forum is taking place in Washington, D.C.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc., led by Chairman and CEO Fuad El-Hibri, is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax^(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent’s product pipeline targets infectious diseases and includes programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional information may be found at www.emergentbiosolutions.com.

About the NATO Parliamentary Assembly

The NATO Parliamentary Assembly is the inter-parliamentary organization of legislators from the member countries of the North Atlantic Alliance as well as 14 associate members. The Assembly provides a critical forum for international parliamentary dialogue on an array of security, political and economic matters. For more information, visit www.nato-pa.int.

“Mr. White’s expertise in financial management, gained in a patient-focused health care system and service-oriented environment, will prove an invaluable asset in guiding Emergent’s management team towards further growth and in increasing value for shareholders,” Fuad El-Hibri, Emergent BioSolutions, Inc.’s chairman and CEO, said. “We are delighted to welcome him to Emergent’s Board of Directors, composed of seasoned experts with diverse skill sets.”

White, who currently serves as system vice president and chief financial officer of St. Vincent Health, one of the largest health care systems in Indiana, said he is excited about the appointment to Emergent BioSolutions, Inc.’s board of directors.

“It is an honor to serve on the board of a company whose mission is to protect life by providing and developing life-saving vaccines and treatments that benefit public health,” White said. “Through this opportunity, I look forward to contributing to Emergent’s success by drawing from my experience in health care systems and pharmaceuticals as well as my efforts in philanthropy.”

• The Jefferies & Company 2010 Global Life Sciences Conference
  New York, NY.
  June 8, 2010
  Corporate Overview Presentation
  11:00 AM Eastern
  There will be a full webcast with slides that will include discussion of the Company’s business activities, financial outlook and current news.

• The Needham & Company 9^th Annual Healthcare Conference
  New York, NY.
  June 10, 2010
  Corporate Overview Presentation
  3:20 PM Eastern
  There will be a full webcast with slides that will include discussion of the Company’s business activities, financial outlook and current news.

Both webcasts will be accessible from the Emergent website www.emergentbiosolutions.com under “Investors”.

“Strengthening the Biological Weapons Convention and international cooperation in biodefense are of paramount importance. This forum organized by Emergent is extremely valuable in helping us, as national legislators, to obtain more information on biopreparedness and to promote the idea of strengthening national biodefense capabilities using the best practices and expertise developed by our Allies,” said Canadian Senator Pierre Claude Nolin, NATO PA Treasurer and Vice Chairman of the NATO PA Science and Technology Committee. “We are firm believers in international mechanisms to address bioterrorism challenges.”

The forum is to provide an overview of the United States’ approach to bioterrorism prevention, the role of the Department of Defense and the importance of coordination of international efforts. Featured speakers include: Congressman Mike Rogers (R-MI), Dr. Robert P. Kadlec, Director of PRTM Biodefense and Public Health Practice, Jim Saxton, former Member of the U.S. House of Representatives, and Dr. Tevi Troy, Senior Visiting Fellow at the Hudson Institute and former Deputy Director of the U.S. Department of Health and Human Services.  The visiting delegation, led by NATO Officers of the Science and Technology Committee, is composed of parliamentarians from representative NATO nations including Canada, the Czech Republic, France, and Portugal. The forum is taking place in Washington, D.C.

Fuad El-Hibri

The conference addressed the challenges key stakeholders will face in a changing healthcare system and offered information on how to foster continued excellence.  Emergent Biosolutions, LLC, led by CEO and Yale School of Management alumnus, Fuad El-Hibri, co-sponsored the conference.  For more information, please see http://www.yalehealthcare.com/advisory.php.